206 related articles for article (PubMed ID: 21131760)
1. Biological response modifiers: current use and future prospects in cancer therapy.
Bisht M; Bist SS; Dhasmana DC
Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
[TBL] [Abstract][Full Text] [Related]
2. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
3. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
4. Cancer treatment: what's ahead?
Parvez T
J Coll Physicians Surg Pak; 2005 Nov; 15(11):738-45. PubMed ID: 16300718
[TBL] [Abstract][Full Text] [Related]
5. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
6. Biologic response modifiers in cancer therapy: a review.
Quesada JR
Tex Med; 1989 Nov; 85(11):42-7. PubMed ID: 2686076
[TBL] [Abstract][Full Text] [Related]
7. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
8. [Combination of chemotherapy and immunotherapy in man--review].
Ohnuma T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic approaches for the treatment of malignant melanoma.
Curiel-Lewandrowski C; Atkins MB
Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
[TBL] [Abstract][Full Text] [Related]
10. [Tumoricidal biological response modifiers (BRM)].
Niitsu Y; Kohgo Y; Watanabe N
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Vaccines and vaccine adjuvants as biological response modifiers.
Speil C; Rzepka R
Infect Dis Clin North Am; 2011 Dec; 25(4):755-72. PubMed ID: 22054754
[TBL] [Abstract][Full Text] [Related]
13. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
Shen RN; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
[TBL] [Abstract][Full Text] [Related]
14. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
[No Abstract] [Full Text] [Related]
15. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
Gjerstorff MF; Burns J; Ditzel HJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
[TBL] [Abstract][Full Text] [Related]
16. [A drug delivery system and biological response modifiers for the treatment of mycobacterial infection].
Koga H; Miyazaki Y; Kohno S; Hara K
Kekkaku; 1994 Feb; 69(2):113-8. PubMed ID: 8126987
[TBL] [Abstract][Full Text] [Related]
17. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
18. Locoregional treatment of malignant hepatic tumors with biologic response modifiers.
Yamamoto A; Sato T
Surg Oncol Clin N Am; 2008 Oct; 17(4):935-55, xii. PubMed ID: 18722927
[TBL] [Abstract][Full Text] [Related]
19. Immunological approach in the diagnosis, therapy and prognosis of the exocrine pancreatic cancer.
Bădulescu F; Bădulescu A; Rogoz S; Mustaţă R
Roum Arch Microbiol Immunol; 2001; 60(1):5-16. PubMed ID: 11850897
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy as part of combinations for the treatment of cancer.
Mitchell MS
Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]